Form 4: Srinivas Akkaraju, Mineralys Therapeutics Director, Acquires 600,000 Shares

Director Srinivas Akkaraju reports the acquisition of 600,000 shares of Mineralys Therapeutics at $13.50 per share through Samsara BioCapital, L.P.

Summary

• Srinivas Akkaraju, a director of Mineralys Therapeutics, Inc. (MLYS), reported a transaction on March 13, 2025.
• Mr. Akkaraju acquired 600,000 shares of Common Stock at a price of $13.50 per share.
• The shares were acquired indirectly through Samsara BioCapital, L.P.
• Following the transaction, Mr. Akkaraju beneficially owns 5,674,916 shares indirectly through Samsara BioCapital, L.P.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing a significant amount of shares usually indicates confidence in the company, but it's also a routine transaction that needs to be disclosed.

Positives

• A director's purchase of a significant number of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings provide transparency to the market and allow investors to track insider activity, which can sometimes offer insights into a company's prospects.

Key Dates